RBC Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY), 'HELIOS-B Likely To Hit The Primary Endpoint And We See Upside Post Recent Pullback'
Tweet Send to a Friend
RBC Capital analyst Luca Issi reiterated an Outperform rating and $235.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
